IRIS International Announces Third Quarter 2011 Revenue and Financial Results
03. November 2011 16:05 ET
|
IRIS International, Inc.
Record revenue of $28.1 million; 9% growth over Q3 2010
Gross margin of 50% in Q3 2011; Excluding Arista, gross margin of 52%
Restructured Personalized Medicine Division by downsizing...
IRIS International to Host Investor Breakfast December 2nd, 2011 In New York
31. Oktober 2011 09:00 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Receives CE Mark for Its NADiA ProsVue(TM) Prognostic Cancer Test
26. Oktober 2011 18:43 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS to Release Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 3, 2011
17. Oktober 2011 16:10 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 17, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Reports Granting of Inducement Awards
14. Oktober 2011 16:15 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., Oct. 14, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and...
IRIS International Receives FDA 510(k) Clearance for Its NADiA ProsVue(TM) Prognostic Cancer Test
22. September 2011 13:48 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., Sept. 22, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of...
IRIS International Announces Restructuring of Personalized Medicine Division
07. September 2011 16:05 ET
|
IRIS International, Inc.
Discontinuing non-proprietary testing services – flow cytometry, FISH, cytology services and molecular pathology menu
Retaining CLIA license and commercial capabilities for the...
IRIS International Announces Second Quarter 2011 Revenue and Financial Results
03. August 2011 16:01 ET
|
IRIS International, Inc.
Record Revenue of $30.2 Million; 13% Growth Over Q2 2010
Gross Margin of 52% in Q2 2011
Net Loss of $0.3 Million or Diluted ($0.02) Per Share, Which Includes Arista Net...
IRIS to Release Second Quarter Financial Results and Host Conference Call and Webcast on Wednesday, August 3, 2011
26. Juli 2011 07:00 ET
|
IRIS International, Inc.
CHATSWORTH, Calif., July 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), will release its 2011 second quarter financial results after the close of trading on Wednesday, August 3,...
IRIS Introduces the iRICELL(R)1500 Workcell for the U.S. Market at AACC 2011 Annual Meeting and Clinical Lab Expo
25. Juli 2011 07:00 ET
|
IRIS International, Inc.
ATLANTA, July 25, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value...